Prospective study of hepatitis B virus reactivation in patients with hematological malignancies

Maurizio Pompili, Stefan Hohaus, Antonio Grieco, Livio Pagano, Simona Sica, Lorenzo Nosotti, Mariella D’Andrea, Susanna Fenu, Concetta Mirisola

Risultato della ricerca: Contributo in rivistaArticolo in rivista

11 Citazioni (Scopus)

Abstract

Background and aim. The best strategy for managing patients with resolved hepatitis B virus infection (HBsAg negative, anti-HBc antibodies positive with or without anti-HBs antibodies) and hematological malignancies under immunosuppressive therapies has not been defined. The aim of this study was to prospectively analyze the risk of hepatitis B virus reactivation in these patients. Material and methods. Twenty-three patients (20 positive for anti-HBs) were enrolled. Eleven patients underwent hematopoietic stem cell transplantation (autologous in 7 cases, allogeneic in 4 cases) while the remaining 12 were treated with immunosuppressive regimens (including rituximab in 9 cases). Results. During the study no patient presented acute hepatitis. However, three anti-HBc/anti-HBs positive patients who were treated with allogeneic hematopoietic stem cell transplantation demonstrated hepatitis B virus reactivation within 12 months from transplant. No one of the remaining patients showed hepatitis B virus reverse seroconversion. Conclusions. Allogeneic hematopoietic stem cell transplantation is a high risk condition for late hepatitis B virus reactivation in patients with resolved infection. Reverse seroconversion seems to be a rare event in anti-HBc/anti-HBs positive patients submitted to autologous hematopoietic stem cell transplantation or systemic chemotherapy with or without rituximab.
Lingua originaleEnglish
pagine (da-a)168-174
Numero di pagine7
RivistaAnnals of Hepatology
Volume14
Stato di pubblicazionePubblicato - 2015

Keywords

  • hepatitis
  • lymphoma

Fingerprint Entra nei temi di ricerca di 'Prospective study of hepatitis B virus reactivation in patients with hematological malignancies'. Insieme formano una fingerprint unica.

Cita questo